Developing Novel Integrated Point-of-Care Systems for Chronic Kidney Disease Biomarkers Measurements

开发用于慢性肾脏病生物标志物测量的新型集成护理点系统

• 批准号: 462376-2014
• 负责人: Lin, Francis
• 金额: $ 6.6万
• 依托单位: University of Manitoba
• 依托单位国家: 加拿大
• 项目类别: Collaborative Health Research Projects
• 财政年份: 2015
• 资助国家: 加拿大
• 起止时间: 2015-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=576909
• 关键词: Developing; Novel; Integrated; Point; Care

Chronic kidney disease (CKD) is a growing health problem that affects roughly 1.2 million Canadians. Untreated, CKD can lead to kidney failure, a condition that requires treatment with dialysis. Once on dialysis, patients experience poor health and a low quality of life. In addition, dialysis is a very expensive treatment for the Canadian Health System to provide, costing roughly $55,000-$80,000 per patient per year. Kidney failure and dialysis can be prevented if CKD is recognized early. For this reason, the National Kidney Foundation has declared early identification and treatment of CKD to be a priority. Unfortunately, our current ways of finding patients who are at risk of kidney failure are not perfect. Newer tests (biomarkers) have been created that could make finding patients at high risk of kidney failure better, but right now using these tests in clinics is difficult and expensive. Microfluidic Lab-on-Chip (LOC) based systems could make using these new tests easier and less expensive. In this project, we will develop convenient and easy-to-use microfluidic LOC systems for doing 5 of these new tests (hsCRP, NT-proBNP, FGF-23, IL-6, microRNA). Once developed we will then test how well these systems improve the care of patients with kidney disease in the real world.

慢性肾脏疾病(CKD)是一个日益严重的健康问题，影响着大约120万加拿大人。如果不治疗，CKD可以 导致肾衰竭，这是一种需要透析治疗的疾病。一旦接受透析，患者的健康状况就会变差， 低质量的生活。此外，透析是加拿大卫生系统提供的一种非常昂贵的治疗， 每个患者每年大约55,000-80,000美元。如果及早发现慢性肾脏病，肾功能衰竭和透析是可以预防的。为 因此，国家肾脏基金会已宣布CKD的早期识别和治疗是优先事项。 不幸的是，我们目前寻找有肾衰竭风险的患者的方法并不完美。较新的检测(生物标志物) 已经创建了可以更好地找到肾衰竭高危患者的方法，但现在在 诊所是困难和昂贵的。基于微流控芯片实验室(LOC)的系统可以使使用这些新测试变得更容易 而且更便宜。在这个项目中，我们将开发方便易用的微流控LOC系统，用于以下五个方面 这些新的检测(hsCRP、NT-proBNP、成纤维细胞生长因子-23、IL-6、microRNA)。一旦开发完成，我们将测试这些系统的运行情况 改善现实世界中肾病患者的护理。